Case Study

ECO Animal Health & Ghent University: Exclusive Worldwide Development and Licensing Deal for Poultry Vaccine


Resulting from an introduction through IN-PART’s online matchmaking platform for university-industry collaboration, ECO Animal Health (ECO) have signed a worldwide exclusive development and licensing deal with Ghent University. This deal allows ECO to further develop, register and commercialise a Clostridium perfringens vaccine for poultry based on antigens co-developed by Professor Filip Van Immerseel (Faculty of Veterinary Medicine, Ghent University) and Professor Rick Titball (College of Life and Environmental Sciences, University of Exeter).

This new collaboration comes at a time of global concern for the spread of antibiotic-resistant bacteria. Clostridium perfringens is a bacterium that normally inhabits the gastrointestinal system of chickens, but when predisposing triggers are present, specific strains can cause necrotic enteritis with major consequences for bird health and growth.

It’s hoped that this new collaboration between ECO Animal Health and Ghent University could lead to a preventative vaccine for C. perfringens that will significantly reduce yield losses and provide an additional sustainable tool for the management of necrotic enteritis.

Steve Wilson, Global Project Leader in Biologics at ECO, was introduced to the PROVAXS team at Ghent University through IN-PART’s matchmaking platform in the summer of 2018. Steve explained how the collaboration developed:

“The initial conversation, following the signature of a CDA, was very much technically focused, gathering as much information about the technology and possible benefits from it. This, combined with company technical and commercial reviews, led to the drafting of term sheets and latterly the R&D agreement to further validate the technology prior to licensure.”

Elaborating on the development and licensing deal with Ghent University, Steve outlined that:

“ECO Animal Health has entered into an R&D agreement to conduct further work prior to licence option, and during the coming months we will conduct some additional studies to further validate the technology as a vaccine formulation. The IN-PART introduction was invaluable as ECO Animal Health may not have been aware of the technology Ghent was offering without it.”

Professor Van Immerseel, from the Faculty of Veterinary Medicine at Ghent University said:

“We look forward to collaborating with ECO Animal Health on the development of this candidate vaccine into a practical tool for the prevention of necrotic enteritis thereby further supporting the global poultry industry in adopting a sustainable approach to the management of this disease.”

Peter Lawrence, the Non-Executive Chairman of ECO Animal Health commented:

“We are delighted to have entered into this collaboration with Ghent University. Necrotic enteritis can result in a significant reduction in body weight and increase in feed conversion rate when compared with healthy broilers.”


This article has also been published by:

The article is an extended version of a public domain announcement published by ECO Animal Health: https://www.businesswire.com/news/home/20190212006078/en/ECO-Animal-Health-UK-Regulatory-Announcement-Statement


Read more case studies of collaborations that started through IN-PART’s matchmaking platform for university-industry collaboration.


Copyrights reserved unless otherwise agreed – IN-PART Publishing Ltd., 2019


About IN-PART:

IN-PART unlocks innovation from research by making new connections between academia and industry to get ideas out of the lab and onto the market.

With proactive community engagement underpinned by smart matching algorithms, IN-PART’s online matchmaking platform connects the requirements of R&D-driven companies with the most relevant innovation being developed by academics at institutes around the world.


ECO Animal Health & Ghent University - Clostridium perfringens Vaccine - IN-PART Case Study - Header Image

Header image background: Artem Bali / Unslpash (CC0)